Department of Defense Anthrax Vaccine Immunization Program Avip: Unproven Force Protection, Hearing Before the Committee on Government Reform, U.S. House of Representatives, April 3, 2000

Portada
Dan Burton
DIANE Publishing, 2000 - 67 páginas
Responding to service members' complaints of program insensitivity to adverse health effects, inadequate medical record-keeping, & heavy-handed program operation, the Committee initiated an oversight investigation into the design & implementation of the DoD force-wide, mandatory Anthrax Vaccine Immunization Program. The Committee measured the program against this standard: any expanded use of the same vaccine should be undertaken only with the greatest care & only to the extent necessary. As currently designed & implemented, the Anthrax Vaccine Immunization Program fails on both counts. The Anthrax Vaccine Immunization Program lacks a consistent standard of care & is designed to reach far beyond those at risk.
 

Comentarios de la gente - Escribir un comentario

No encontramos ningún comentario en los lugares habituales.

Páginas seleccionadas

Términos y frases comunes

Pasajes populares

Página 1 - The Chairman was directed to transmit a copy to the Speaker of the House. I. INTRODUCTION...
Página 43 - Comparative efficacy of Bacillus anthracis live spore vaccine and protective antigen vaccine against anthrax in the guinea pig.
Página 44 - Presently there are no precise scrological or other immunological correlates of protection to enable conclusions to be drawn from immunization studies in man. The extrapolation from animal studies to humans likewise is seriously complicated by this fact Reference is made to licensure issues for Diphtheria toxoid and Pertussis vaccine.
Página 61 - BEFORE THE SUBCOMMITTEE ON NATIONAL SECURITY, VETERANS AFFAIRS AND INTERNATIONAL RELATIONS, HOUSE COMMITTEE ON GOVERNMENT REFORM ON THE STANDARD PROCUREMENT SYSTEM FEBRUARY 7, 2002 Mr.
Página 7 - Mr. Louis J. Rodrigues Director, Defense Acquisitions Issues National Security and International * Affairs Division US General Accounting Office Washington, DC 20548 Dear Mr. Rodrigues...
Página 61 - ... review of manufacturing and clinical trials and subsequent clinical laboratory experience with the vaccine; second — ongoing inspections of the manufacturing facility; third— our lot release requirements; and fourth — our ongoing collection and analysis of adverse event reports. So far, the data gathered from VAERS reports on anthrax vaccine do not signal concerns about the safety of the vaccine. The Agency will continue to closely monitor and investigate reports of serious adverse events...
Página 58 - Foundation, the Assistant to the President for National Security Affairs, and the Assistant to the President for Policy Development.
Página 9 - ... hazardous risk associated with potentially severe adverse reactions and the potential lack of efficacy of the AVA. And then it goes on to say these concerns stem from. A. the limited use of the vaccine to date, ie tests prior to the approval of the vaccine by the Food and Drug Administration on two small a scale to permit accurate assessment of types and severity of adverse reactions — only widespread use can provide this assessment — and, B. insufficient experience in mass immunization programs...
Página 41 - Third, quality can be guaranteed not from final tests on random samples but only from a combination of in-process tests, end-product tests, and strict controls of the entire manufacturing process...

Información bibliográfica